StemCyte International Ltd (4178)

Currency in TWD
17.50
-0.30(-1.69%)
Closed·
4178 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
17.5017.80
52 wk Range
16.6034.10
Key Statistics
Bid/Ask
17.50 / 17.55
Prev. Close
17.5
Open
17.8
Day's Range
17.5-17.8
52 wk Range
16.6-34.1
Volume
115.81K
Average Volume (3m)
398.71K
1-Year Change
-31.5068%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
4178 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales decline in the current year

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Earnings

Latest Release
May 15, 2026
EPS / Forecast
-0,19 / --
Revenue / Forecast
87,81M / --
EPS Revisions
Last 90 days

4178 Income Statement

Compare 4178 to Peers and Sector

Metrics to compare
4178
Peers
Sector
Relationship
P/E Ratio
−21.1x−16.8x−0.4x
PEG Ratio
−2.81−0.530.00
Price/Book
2.2x3.3x2.6x
Price / LTM Sales
10.6x47.1x3.1x
Upside (Analyst Target)
-60.4%47.9%
Fair Value Upside
Unlock−8.3%6.3%Unlock

StemCyte International, Ltd., a biotechnology company, develops cord blood–based cell therapies in the United States and Taiwan. The company engages in the research and development of biotechnology and cell-based new drugs; supply of cellular materials; and operation of cord blood cell banks. It also offers umbilical cord blood transplantation services; and cell products and services. In addition, the company provides REGENECYTE, an allogeneic umbilical cord blood cellular biotherapy for the treatment of cancer, hematological disorders, immune-related conditions, and metabolic disorders, as well as for post-covid, acute stroke, and cerebral palsy. Further, it develops CB201(CB-NK), an API in preclinical development for the treatment of hematological malignancies. The company was founded in 1997 and is based in Taipei, Taiwan. StemCyte International, Ltd. operates as a subsidiary of Diamond Biofund Inc.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
0,000,00%0,00
Other Institutional Investors
104,60M48,45%1,86B
Public Companies & Retail Investors
111,27M51,55%1,98B
Total
215,87M100,00%3,84B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Diamond Biofund Inc.15,26%32 937 150586 281
Diamond Biofund I Inc.6,95%15 000 000267 000

FAQ

What Is the StemCyte International (4178) Stock Price Today?

The StemCyte International stock price today is 17,50 TWD.

What Stock Exchange Does StemCyte International Trade On?

StemCyte International is listed and trades on the Taiwan Stock Exchange.

What Is the Stock Symbol for StemCyte International?

The stock symbol for StemCyte International is "4178."

What Is the StemCyte International Market Cap?

As of today, StemCyte International market cap is 3,78B TWD.

What Is StemCyte International's Earnings Per Share (TTM)?

The StemCyte International EPS (TTM) is -0,93.

From a Technical Analysis Perspective, Is 4178 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has StemCyte International Stock Split?

StemCyte International has split 0 times.

What is the current trading status of StemCyte International (4178)?

As of Aug 18, 2026, StemCyte International (4178) is trading at a price of 17,50 TWD, with a previous close of 17,50 TWD. The stock has fluctuated within a day range of 17,50 TWD to 17,80 TWD, while its 52-week range spans from 16,60 TWD to 34,10 TWD.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.